Arctic Bioscience Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Christer Valderhaug
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.2% |
| Management average tenure | 7.3yrs |
| Board average tenure | 5yrs |
CEO
Christer Valderhaug (53 yo)
Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 10.3yrs | no data | 0.074% NOK 65.6k | |
| Chief Executive Officer | no data | no data | 0.21% NOK 189.0k | |
| Founder & Chief Scientific Officer | 7.8yrs | no data | 1.71% NOK 1.5m | |
| Chief Financial Officer | 3.8yrs | no data | 0.049% NOK 43.3k | |
| Chief Operating Officer | 13.5yrs | no data | 0.085% NOK 75.2k | |
| Chief Technical Officer | 13.5yrs | no data | 0.22% NOK 193.0k | |
| Senior Vice President of Sales & Marketing | 3.8yrs | no data | no data | |
| Executive Vice President of Global Business Development | 7.3yrs | no data | no data | |
| Global Medical Director | 6.4yrs | no data | 0.13% NOK 114.1k | |
| Regulatory Manager | no data | no data | 0.030% NOK 26.2k |
Experienced Management: ABS's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 10.3yrs | no data | 0.074% NOK 65.6k | |
| Board Member | 5yrs | no data | 11.46% NOK 10.1m | |
| Board Member | 10.3yrs | no data | 3.86% NOK 3.4m | |
| Director | 5yrs | no data | no data | |
| Director | less than a year | no data | no data |
Experienced Board: ABS's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 12:50 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arctic Bioscience AS is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Carnegie |
| Geir Holom | DNB Carnegie |